Michael Ulz

Stock Analyst at Morgan Stanley

(3.72)
# 659
Out of 4,765 analysts
118
Total ratings
46.67%
Success rate
8.57%
Average return
Main Sectors:
Top Industries:

Stocks Rated by Michael Ulz

Aardvark Therapeutics
Mar 10, 2025
Initiates: Overweight
Price Target: $29
Current: $10.54
Upside: +175.14%
Y-mAbs Therapeutics
Mar 5, 2025
Maintains: Underweight
Price Target: $11$7
Current: $4.89
Upside: +43.15%
Silence Therapeutics
Mar 5, 2025
Maintains: Overweight
Price Target: $49$45
Current: $4.20
Upside: +971.43%
Karyopharm Therapeutics
Mar 3, 2025
Maintains: Outperform
Price Target: $75$54
Current: $7.50
Upside: +620.00%
Iovance Biotherapeutics
Feb 28, 2025
Maintains: Outperform
Price Target: $24$20
Current: $3.82
Upside: +423.56%
Alnylam Pharmaceuticals
Feb 14, 2025
Maintains: Equal-Weight
Price Target: $275$284
Current: $240.79
Upside: +17.95%
Third Harmonic Bio
Feb 12, 2025
Downgrades: Equal-Weight
Price Target: $20$5
Current: $3.50
Upside: +42.86%
Fractyl Health
Feb 3, 2025
Maintains: Overweight
Price Target: $18$10
Current: $1.37
Upside: +629.93%
Akero Therapeutics
Jan 28, 2025
Maintains: Overweight
Price Target: $46$96
Current: $45.23
Upside: +112.25%
Viking Therapeutics
Sep 12, 2024
Reiterates: Overweight
Price Target: $105
Current: $29.35
Upside: +257.75%
Maintains: Overweight
Price Target: $48$52
Current: $12.21
Upside: +325.88%
Maintains: Equal-Weight
Price Target: $110$115
Current: $89.90
Upside: +27.92%
Maintains: Overweight
Price Target: $53$57
Current: $45.52
Upside: +25.23%
Maintains: Equal-Weight
Price Target: $36$27
Current: $15.68
Upside: +72.19%
Initiates: Overweight
Price Target: $40
Current: $2.54
Upside: +1,474.80%
Maintains: Equal-Weight
Price Target: $3$7
Current: $0.99
Upside: +607.07%
Downgrades: Underweight
Price Target: $23$12
Current: $9.50
Upside: +21.05%
Maintains: Overweight
Price Target: $28$25
Current: $1.91
Upside: +1,208.90%
Maintains: Equal-Weight
Price Target: $45$48
Current: $33.13
Upside: +44.88%
Maintains: Outperform
Price Target: $15$27
Current: $8.00
Upside: +237.50%
Maintains: Equal-Weight
Price Target: $30$20
Current: $3.32
Upside: +502.41%
Initiates: Overweight
Price Target: $45
Current: $8.76
Upside: +413.70%
Maintains: Overweight
Price Target: $20$10
Current: $0.82
Upside: +1,119.51%
Maintains: Equal-Weight
Price Target: $6$8
Current: $0.25
Upside: +3,165.31%
Downgrades: Equal-Weight
Price Target: $3
Current: $1.75
Upside: +71.43%
Upgrades: Equal-Weight
Price Target: $18$30
Current: $7.22
Upside: +315.51%
Maintains: Equal-Weight
Price Target: $25$30
Current: $1.35
Upside: +2,122.22%
Initiates: Outperform
Price Target: $45
Current: $7.50
Upside: +500.00%
Maintains: Outperform
Price Target: $12$20
Current: $0.51
Upside: +3,833.14%
Maintains: Outperform
Price Target: $85$80
Current: $40.42
Upside: +97.92%
Maintains: Outperform
Price Target: $12$15
Current: $8.92
Upside: +68.16%